Hagens Berman Notifies Osiris Therapeutics, Inc. Investors of Class Action Settlement and January 30, 2019 Claims Deadline
San Francisco - National investor-rights law firm Hagens Berman Sobol Shapiro LLP reached a settlement on behalf of investors in Osiris Therapeutics, Inc. (NASDAQ: OSIR) (“Osiris” or the “Company”) who purchased shares between May 12, 2014 and November 16, 2015. The class action alleged violations of the federal securities laws. Named as defendants were Osiris, Lode Debrabandere, Gregory Law and Philip R. Jacoby, Jr. Settlement is pending final approval.
Class Members have until January 30, 2019 to submit a Proof of Claim and Release to receive a payment from the class action settlement.
If you purchased or otherwise acquired Osiris shares between May 12, 2014, and November 16, 2015, you may submit a claim for the settlement by visiting the following link to download the claim form.
You may mail your completed and signed Proof of Claim and Release, postmarked no later than January 30, 2019, to the Settlement Administrator at:
Osiris Securities Settlement
P.O. Box 4129
Portland, OR 97208-4129
# # #
About Hagens Berman
Hagens Berman is a national investor-rights law firm headquartered in Seattle, Washington with 80+ attorneys in 10 offices across the country. The Firm represents investors, whistleblowers, workers and consumers in complex litigation. More about the firm and its successes can be found at www.hbsslaw.com. For the latest news visit our newsroom or follow us on Twitter at @classactionlaw.
Hagens Berman purchases advertisements on search engines, social media sites and other websites. Transmission of the information contained or available through this website is not intended to create, and receipt does not constitute, an attorney-client relationship. If you seek legal advice or representation by Hagens Berman, you must first enter a formal agreement. All information contained in any transmission is confidential and Hagens Berman agrees to protect information against unauthorized use, publication or disclosure. This site is regulated by the Washington Rules of Professional Conduct.